Merck Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Merck şirketinin toplam hissedar öz sermayesi $44.6B ve toplam borcu $38.1B olup, bu da borç-öz sermaye oranını 85.6% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $117.5B ve $73.0B dir. Merck 'in FAVÖK'ü $18.9B faiz karşılama oranı 20.7 dur. Şirketin $14.6B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

85.6%

Borç/özkaynak oranı

US$38.13b

Borç

Faiz karşılama oranı	20.7x
Nakit	US$14.59b
Eşitlik	US$44.56b
Toplam yükümlülükler	US$72.97b
Toplam varlıklar	US$117.53b

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: MRKD 'nin kısa vadeli varlıkları ( $40.4B ) kısa vadeli yükümlülüklerini ( $29.6B ) aşıyor.

Uzun Vadeli Yükümlülükler: MRKD 'un kısa vadeli varlıkları ( $40.4B ) uzun vadeli yükümlülüklerini ( $43.4B ) karşılamamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: MRKD 'nin net borç/öz sermaye oranı ( 52.8% ) yüksek olarak değerlendiriliyor.

Borcun Azaltılması: MRKD 'nin borç/öz sermaye oranı son 5 yılda 96.9% seviyesinden 85.6% seviyesine düştü.

Borç Kapsamı: MRKD 'nin borcu işletme nakit akışı ( 47.9% ) tarafından iyi bir şekilde karşılanmaktadır.

Faiz Kapsamı: MRKD 'in borcuna ilişkin faiz ödemeleri EBIT ( 20.7 x kapsam) tarafından iyi bir şekilde karşılanmaktadır.

Merck Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Merck & Co., Inc. Appoints Surendralal L. Karsanbha to its Board of Directors, Effective January 1, 2025

Merck & Co., Inc.'s WELIREG (Belzutifan) Approves in China for the Treatment of Adult Patients with Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors

Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab with Berahyaluronidase Alfa Met Primary Endpoints

Merck Receives Positive EU CHMP Opinion for KEYTRUDA Plus Chemotherapy as First-Line Treatment for Adult Patients with Unresectable Non-Epithelioid Malignant Pleural Mesothelioma

Alexion, AstraZeneca Rare Disease and Merck Announces Positive Topline Results from the Phase 3 Komet Trial

Merck Announces Canada's Drug Agency Recommends WINREVAIR (sotatercept) for Reimbursement

Merck and Moderna, Inc. Initiates Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA (Pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients with Certain Types of Non-Small Cell Lung Cancer (NSCLC)

CDC's ACIP Recommends Merck's CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults 50 Years of Age and Older

Merck's KEYTRUDA® (Pembrolizumab) Receives 30th Approval from European Commission with Two New Indications in Gynecologic Cancers

Gilead Sciences, Inc. and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48

Merck Announces the Presentation of Positive Results from the Phase 2B/3 Clinical Trial (Mk-1654-004) Evaluating Clesrovimab

Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Adults with Increased Risk for Pneumococcal Disease

Merck & Co., Inc. to Report Q3, 2024 Results on Oct 31, 2024

FDA Approves Merck's KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients with Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma

Merck Announces Overall Survival Results from the Final Analysis of the Phase 3 Keynote-811 Trial Evaluating Keytruda® (Pembrolizumab)

Merck Announces WINREVAIR (Sotatercept) Is Authorized for Use in Canada for Adults with Pulmonary Arterial Hypertension

Merck & Co., Inc. and EyeBio Announce Initiation of Phase 2b/3 Clinical Trial for Restoret™? for the Treatment of Diabetic Macular Edema

European Commission Approves Merck's KEYTRUDA (Pembrolizumab) Plus Padcev (Enfortumab Vedotin-Ejfv) as First-Line Treatment of Unresectable or Metastatic Urothelial Carcinoma in Adults

Merck & Co., Inc. Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 Trials

Merck Receives European Commission Approval for Winrevair (Sotatercept) in Combination with Other Pulmonary Arterial Hypertension (Pah) Therapies, for the Treatment of Pah in Adult Patients with Functional Class II-III

Health Canada Approves Merck's KEYTRUDA® for the Treatment of Adult Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer with No Prior Systemic Therapy for mUC, in Combination with Enfortumab Vedotin

Merck & Co., Inc. Provides Update on Phase 3 KeyVibe-008 Trial Evaluating an Investigational Fixed-Dose Combination of Vibostolimab and Pembrolizumab in Patients With Extensive-Stage Small Cell Lung Cancer

Daiichi Sankyo and Merck Announces IDeate-Lung02 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Relapsed Small Cell Lung Cancer

Merck & Co., Inc. Revises Earnings Guidance for the Year 2024

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin